肠道微生物群与造血细胞移植后复发
该研究对541例接受异基因造血细胞移植(allo-HCT)患者的粪便样本行16S核糖体测序,分析肠道菌群与移植后2年内复发/疾病进展的关系。验证集中以迟缓真杆菌(Eubacterium limosum)为主的菌群丰度较高与复发/进展风险降低相关(每增加10倍丰度HR 0.82,95%CI 0.71-0.95,P=.009);该菌群存在与否亦与复发/进展风险相关(HR 0.52,95%CI 0.31-0.87,P=.01)。
要点
- 验证集中以迟缓真杆菌为主的菌群丰度每增加10倍,复发/进展风险HR 0.82(95%CI 0.71-0.95,P=.009)。
- 该菌群存在者复发/进展风险HR 0.52(95%CI 0.31-0.87,P=.01)。
- 该菌群存在与不存在者2年累积复发/进展率分别为19.8%和33.8%。
核心结论
- 肠道菌群中一组细菌的丰度与allo-HCT后复发/疾病进展存在关联,可能作为预防复发和改善生存的生物标志物或治疗靶点。
研究设计与样本
- 回顾性发现-验证队列研究,对541例因allo-HCT入院患者前瞻性收集的粪便样本行16S核糖体测序,随访2年,采用病因特异性比例风险模型分析。
主要发现
- 验证集中以迟缓真杆菌为主的菌群丰度较高与复发/疾病进展风险降低相关(每增加10倍丰度HR 0.82,95%CI 0.71-0.95,P=.009)。
- 按该菌群存在与否分组,存在该菌群亦与较少的复发/疾病进展相关(HR 0.52,95%CI 0.31-0.87,P=.01)。
- 存在与不存在该菌群的患者2年累积复发/进展率分别为19.8%和33.8%。
- 上述关联在多变量模型中仍显著,且在接受T细胞充足移植物受者中最强。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The major causes of mortality after allogeneic hematopoietic-cell transplantation (allo-HCT) are relapse, graft-versus-host disease (GVHD), and infection. We have reported previously that alterations in the intestinal flora are associated with GVHD, bacteremia, and reduced overall survival after allo-HCT. Because intestinal bacteria are potent modulators of systemic immune responses, including antitumor effects, we hypothesized that components of the intestinal flora could be associated with relapse after allo-HCT. Methods The intestinal microbiota of 541 patients admitted for allo-HCT was profiled by means of 16S ribosomal sequencing of prospectively collected stool samples. We examined the relationship between abundance of microbiota species or groups of related species and relapse/progression of disease during 2 years of follow-up time after allo-HCT by using cause-specific proportional hazards in a retrospective discovery-validation cohort study. Results Higher abundance of a bacterial group composed mostly of Eubacterium limosum in the validation set was associated with a decreased risk of relapse/progression of disease (hazard ratio [HR], 0.82 per 10-fold increase in abundance; 95% CI, 0.71 to 0.95; P = .009). When the patients were categorized according to presence or absence of this bacterial group, presence also was associated with less relapse/progression of disease (HR, 0.52; 95% CI, 0.31 to 0.87; P = .01). The 2-year cumulative incidences of relapse/progression among patients with and without this group of bacteria were 19.8% and 33.8%, respectively. These associations remained significant in multivariable models and were strongest among recipients of T-cell-replete allografts. Conclusion We found associations between the abundance of a group of bacteria in the intestinal flora and relapse/progression of disease after allo-HCT. These might serve as potential biomarkers or therapeutic targets to prevent relapse and improve survival after allo-HCT.
引用
- Peled JU, Devlin SM, Staffas A, et al. Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. J Clin Oncol. 2017. PMID: 28296584. doi:10.1200/JCO.2016.70.3348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。